PTPN11 and ovarian carcinoma: In a first-in-human trial of various tumor models, including BRAFV600E-mutant colorectal cancer and KRASG12D-mutant ovarian cancer, after disease progression on monotherapy with PF-07284892, an allosteric SHP2 inhibitor, a combination of encorafenib with binimetinib was administered in addition to PF-07284892.